Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yan, Haijiao
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer	Recruiting	3	392	RoW	TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Advanced Biliary Cancer	03/22	02/23
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification Dec 2020 - Dec 2020: NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification	Recruiting	2a	80	RoW	Infigratinib, BGJ398	LianBio LLC	Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor	12/22	12/23
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study	Recruiting	2	276	RoW	LM302+Toripalimab, LM302+JS001	LaNova Medicines Zhejiang Co., Ltd.	Gastric Cancer, Pancreatic Cancer	07/25	01/26